로딩 중…
지수 로딩 중…
BioNote, Inc.
377740· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,655-0.96%
2026-09-18
Financials
Valuation Metrics
BioNote, Inc.'s Market Cap is ₩4743B. At end of 2025 it was ₩5573B. Ranked #483 of 2,421 in KR market (top 20%), #306 of 781 on KOSPI (top 39%), #53 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 474.28B KRW | KR#483/2,421 Sec#53/231 |
| Revenue | 126.41B KRW | KR#1,277/2,421 Sec#78/231 |
| Net Income | -125.69B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 1.56T KRW | KR#363/2,421 Sec#15/231 |
| Net Assets | 1.51T KRW | KR#220/2,421 Sec#9/231 |
| Employees | 313 | KR#768/2,421 Sec#67/231 |
| Value | ||
| P/B | 0.31x | KR#352/2,421 Sec#12/231 |
| P/S | 3.75x | KR#2,065/2,421 Sec#132/231 |
| EV/EBITDA | 22.30x | KR#1,061/2,421 Sec#64/231 |
| FCF Yield | 1.32% | KR#1,110/2,421 Sec#79/231 |
| Profitability | ||
| ROE | -8.32% | KR#1,900/2,421 Sec#140/231 |
| ROA | -8.08% | KR#2,056/2,421 Sec#152/231 |
| Op. Margin | 16.19% | KR#261/2,421 Sec#25/231 |
| Revenue Growth | 12.82% | KR#769/2,421 Sec#74/231 |
| Earnings Growth | -204.60% | KR#1,241/2,421 Sec#84/231 |
| Financial Health | ||
| Debt Ratio | 2.95% | KR#14/2,421 Sec#6/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 6.27B KRW | KR#846/2,421 Sec#57/231 |
| Cash | 17.87B KRW | KR#1,311/2,421 Sec#102/231 |
| Current Ratio | 18.53x | KR#33/2,421 Sec#14/231 |
| Net Debt/EBITDA | -0.87x | KR#408/2,421 Sec#23/231 |
| Dividend | ||
| Div. Yield | 4.90% | KR#291/2,421 Sec#9/231 |
| Div. Growth | 14.00% | KR#533/2,421 Sec#29/231 |
| Performance | ||
| 1Y Return | -23.94% | KR#1,374/2,421 Sec#98/231 |
| 1M Return | -4.32% | KR#1,730/2,421 Sec#136/231 |
| From 52W High | -26.34% | KR#423/2,421 Sec#25/231 |
| 1Y MDD | -29.94% | KR#247/2,421 Sec#15/231 |
| Trading | ||
| Volume | 69,407 shares | KR#963/2,421 Sec#100/231 |
| Trading Value | 322.4M KRW | KR#1,098/2,421 Sec#113/231 |
| Foreign Own. | 0.54% | KR#2,196/2,421 Sec#210/231 |
| Per Share | ||
| EPS | -1,234 KRW | KR—/2,421 Sec—/231 |
| BPS | 14,833 KRW | KR#707/2,421 Sec#47/231 |
Company Info
Bionote, established in 2003 and listed on the KOSPI market in 2022, specializes in animal diagnostic products and bio-content. Utilizing its unique recombinant antigen and antibody manufacturing technology, it produces and distributes diverse diagnostic products and bio-content across over 80 countries. The company is expanding its business into molecular and biochemical diagnostics. It aims to increase global market share by launching fully automated point-of-care diagnostic devices.